Authors:
Danielle Casey, MBA, MLS(ASCP)CM API Vendor Relations Manager
Lauren Kolehmainen, MLS (ASCP)CM, Quality & Compliance Coordinator
Did you know that cervical cancer is the fourth most common cancer among women worldwide?1 Cervical cancer is caused by Human Papilloma Virus (HPV), a common sexually transmitted infection that infects almost all sexually active people at some point - often without any symptoms. Ensuring accurate and reliable testing is critical for early detection and effective prevention.
API's Proficiency Program for HPV helps laboratories monitor the performance of their HPV molecular diagnostic assays.
- Prepared in liquid cytologic preservative and formulated with the inactivated whole genome and human epithelial cells – thoroughly simulating real patient samples
- Commutable and cross-platform compatibility
- Test the entire workflow (including elution and/or extraction)
- Includes high-risk HPV genotypes
Proficiency testing provides laboratories the confidence that their results are accurate, reliable, and trustworthy. For testing as crucial as HPV, where early detection can save lives, why place your trust anywhere else?
Reference:
1. World Health Organization. (2024, March 5). Cervical cancer. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer/
Want to learn more?
Check out the rest of our new and enhanced programs, our full catalog, or request a quote today!